​

Funding Round

Series C - Kinnate Biopharma

Series C - Kinnate Biopharma

Investment Firm

Overview

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.

Announced Date

Aug 26, 2020

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

RA Capital Management

RA Capital Management

RA Capital Management is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

9

Investor Name
Participant InvestorRA Capital Management
Participant InvestorOrbiMed
Participant InvestorForesite Capital
Participant InvestorLeerink Partners
Participant InvestorFidelity

Round Details and Background

Kinnate Biopharma raised $98000000 on 2020-08-26 in Series C

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 19, 2019
Series B - Kinnate Biopharma
5-74.5M
Aug 26, 2020
Series C - Kinnate Biopharma
13-98.0M
Apr 01, 2018
Series A - Kinnate Biopharma
2-22.0M

Recent Activity

There is no recent news or activity for this profile.